- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
August 16th, 2007
By Jack Uldrich August 16, 2007
While reading an interesting article about the link between academic research and commercial products, I stumbled upon an intriguing company experimenting with a novel -- and tiny -- new way to fight cancer.
Insert Therapeutics, a subsidiary of Arrowhead Research (Nasdaq: ARWR), specializes in developing promising nanotechnology-related university research. It seems that Insert Therapeutics is focusing on an innovative new nanotech-based platform for the treatment of cancer, and it's helping to shepherd the platform through the FDA clinical phase process. The drug in question is only in phase 1 of FDA trials, so it still has a long way to go, and there's absolutely no guarantee that it will ever receive final approval.
|Related News Press|
Artificial synapse rivals biological ones in energy consumption June 21st, 2016
Nanometrics Announces Upcoming Investor Events May 10th, 2016
Stealth nanocapsules kill Chagas parasites in mouse models June 22nd, 2016
New nanoparticle technology developed to treat aggressive thyroid cancer: Platform designed to deliver nanotherapy effective in preclinical models of metastatic anaplastic thyroid cancer June 21st, 2016
Interviews/Book Reviews/Essays/Reports/Podcasts/Journals/White papers